Pfizer GMGP – PARP-Inhibitor Combination Therapies: Personalized Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: Inquire with unit
Memorial Deadline: Monday 31st, March 2025
External Deadline: Monday 7th, April 2025
Description
Pfizer Global Medical Grants & Partnerships (GMGP) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s GMGP competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.
For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.
Date RFP Issued: January 21, 2025
Geographic Scope: Canada
Clinical Area: Oncology – Genitourinary
Link to full RFP: PARP-Inhibitor Combination Therapies: Personalized Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Application Due Date: April 7, 2025
Specific Area of Interest: Projects that will be considered for Pfizer support will focus on increasing healthcare professional awareness and knowledge in the following five (5) areas:
- 1. Personalized treatment in mCRPC: Understanding the rationale for PARP inhibitor combinations (including the MOA, latest clinical data, treatment sequencing) and identifying the optimal patient for PARP inhibitor therapy in mCRPC. Tools for patient counselling and shared decision making are also of interest.
- 2. Improved genetic and biomarker testing: Foster best practices in ordering, interpreting, and applying genetic and biomarker test results in clinical practice. Understand and explain the impact to patients (including germline and somatic testing and implementing reflex/mainstream testing). Increase awareness of the Canadian Urological Association (CUA) genetic testing guidelines for prostate cancer.
- 3. Enhanced multidisciplinary collaboration in clinical practice: Promote integration of care and communication between multidisciplinary team members managing mCRPC, including specialists (e.g. medical oncologists, urologists, uro-oncologists, radiation oncologists, pathologists) and health professionals (e.g. nurses, nurse practitioners, general practitioners in oncology (GPOs), pharmacists, genetic counsellors).
- 4. Management of PARP inhibitor therapy and side effects: Education on initiating treatment and preventing, monitoring, and managing side effects; including the role of patient counselling and of multi-disciplinary team members to optimize patient outcomes.
5. Expand education for community and rural HCPs involved in treating mCRPC: Tailor education to integrate the latest data and treatment advancements based on the unmet needs specific to treatment setting; connect community HCPs with specialists in their regions and foster collaboration between academic and community centers.
Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Lori Carpenter (lori.carpenter@pfizer.com).